GLP-1 Weight Loss | Ozempic & Wegovy Timeline

How GLP-1 medications work

GLP-1 receptor agonists (semaglutide in Ozempic and Wegovy) and dual GLP-1/GIP agonists (tirzepatide in Mounjaro and Zepbound) mimic gut hormones after meals. They blunt appetite, slow gastric emptying, and support glucose regulation. Loss comes mainly from lower intake, not direct fat oxidation. Tirzepatide adds GIP signaling. Lifestyle still matters.

Medication comparison

GLP-1 weight-loss brands, active ingredients, typical weekly doses, and trial names
Drug	Ingredient	Typical dose	Trial
Ozempic	Semaglutide	0.25 to 2 mg weekly	STEP
Wegovy	Semaglutide	Up to 2.4 mg weekly	STEP
Mounjaro	Tirzepatide	2.5 to 15 mg weekly	SURMOUNT
Zepbound	Tirzepatide	2.5 to 15 mg weekly	SURMOUNT
STEP / SURMOUNT trial summaries; see primary literature for detail.

Ozempic

Active ingredient: Semaglutide
Typical dose: 0.25 to 2 mg weekly
Key trial: STEP

Wegovy

Active ingredient: Semaglutide
Typical dose: Up to 2.4 mg weekly
Key trial: STEP

Mounjaro

Active ingredient: Tirzepatide
Typical dose: 2.5 to 15 mg weekly
Key trial: SURMOUNT

Zepbound

Active ingredient: Tirzepatide
Typical dose: 2.5 to 15 mg weekly
Key trial: SURMOUNT

STEP / SURMOUNT summaries; confirm with prescribing information.

Why results vary

Trial data reflects averages; your timeline will depend on:

Starting BMI influences both absolute and percentage loss; higher starting weight may correlate with greater total pounds lost, but percentage loss varies.

Diet and exercise adherence matter: medications support lifestyle changes rather than replace them.

Dosage titration schedules differ by drug; it takes 16 to 20 weeks to reach the full maintenance dose (e.g., 2.4 mg for Wegovy or up to 15 mg for Zepbound). The first 4 months are considered the Escalation Phase; the Maintenance Phase only begins once the target dose is reached, which is why early progress may be slower.

Wegovy titration (5 stages)

0.250.51.01.72.4

Each step: 4 weeks → ~16 weeks to maintenance

Genetics, sleep, stress, and injection consistency also affect outcomes.

Use as orientation only; your clinician knows your context.

Track BMI over time

Open the BMI calculator

→

GLP-1 Weight Loss Calculator: Timeline & Projections for Ozempic, Wegovy, Mounjaro, Zepbound

If you're looking into GLP-1 for weight loss, this calculator gives you a trial-based estimate for Ozempic, Wegovy, Mounjaro, or Zepbound. See how dose, plateau periods, and real-world variation can affect the timeline to your goal weight.

What This Calculator Does & Who It's For

Calculator Purpose & Outputs

Enter your starting weight, goal weight, medication, and dose. The calculator uses STEP and SURMOUNT trial data to estimate weekly loss rates, then projects months to goal. You’ll also see BMI at goal and an optional plateau adjustment (30% slower during months 4–6, when many people hit a slowdown).

What You'll Get:

Projected Timeline: Estimated months to reach your goal weight at typical loss rates for your medication and dose. Weight to Lose: Difference between starting and goal weight. BMI at Goal: Body mass index at your target weight. Clinical Trial Reference: Mean percent weight loss from trials at your dose tier. Plateau Note: Common slowdown window (months 4–6).
Not Medical Advice:

This calculator provides estimates based on published averages. Results vary significantly between individuals. It does not diagnose, treat, or advise. Consult your healthcare provider before starting or adjusting any medication.
Who it’s for:

Anyone on or considering Ozempic, Wegovy, Mounjaro, or Zepbound who wants a ballpark timeline. Useful if you’re wondering “how long will it take?” or comparing drugs. Not a substitute for your doctor’s guidance.

How the Math Works

The projection model derives a weekly loss rate from published clinical trial data. Each medication and dose carries a reference percentage, for example, Wegovy 2.4 mg showed approximately 14.9% mean body-weight loss over 68 weeks in the STEP 1 trial. The weekly rate for any starting weight is:

\text{rate} = \frac{\text{start weight} \times \text{trial \%}}{\text{trial weeks}}

Time to goal follows directly:

\text{weeks to goal} = \frac{\text{weight to lose}}{\text{weekly rate}}

Worked example: a 250 lb person on Wegovy 2.4 mg → rate = (250 × 0.149) ÷ 68 ≈ 0.548 lbs/week; losing 40 lbs takes roughly 40 ÷ 0.548 ≈ 73 weeks. When the plateau toggle is enabled, the calculator slows the rate by approximately 30% during weeks 16–26 (months 4–6) to model the metabolic adaptation many users experience. These projections use population-level averages; individual results vary based on adherence, diet, physical activity, and genetics.

How to Use This Calculator

Enter your current weight and goal weight in pounds or kilograms, the calculator computes the total amount to lose and your BMI at goal. Select your GLP-1 medication from the dropdown: Ozempic, Wegovy, Mounjaro, or Zepbound. Choose the dose that matches your current weekly injection; higher doses generally correspond to faster average loss in trial data. Toggle the plateau adjustment on if you want the projection to model a roughly 30% slowdown during months 4–6, reflecting the common metabolic adaptation period. The results display estimated months to reach your goal, the clinical trial reference percentage for your medication and dose, and a note about the plateau window. Treat the timeline as a planning range, not a guarantee, your healthcare provider can help interpret it alongside your individual response and medical history.

How GLP-1 Drugs Work for Weight Loss

GLP-1 Receptor Agonists

GLP-1 agonists (semaglutide, tirzepatide) mimic a gut hormone that curbs appetite and slows gastric emptying. Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide, which also targets GIP receptors.

Ozempic & Wegovy (Semaglutide):

Ozempic is approved for Type 2 diabetes at 0.25–2 mg weekly. Wegovy is approved for obesity at up to 2.4 mg weekly. STEP trials showed mean weight loss of ~14.9% over 68 weeks at the highest dose.
Mounjaro & Zepbound (Tirzepatide):

Tirzepatide is a dual GLP-1/GIP agonist. Mounjaro is for diabetes; Zepbound is for obesity. SURMOUNT trials showed ~15–21% mean weight loss over 72 weeks depending on dose (5, 10, or 15 mg).
Mechanism:

Weight loss occurs primarily through reduced calorie intake, the drugs make it easier to eat less. They do not directly burn fat. Diet and physical activity still matter for long-term success.

Using This Calculator by Medication

Using this as a Wegovy weight loss calculator

Choose Wegovy in the dropdown and match your current dose. Early progress can look slower because titration usually takes about 16 weeks before the 2.4 mg maintenance stage. If your estimate lengthens when plateau is enabled, that is usually reflecting the common months 4–6 slowdown, not a sign that nothing is working.

Dose context:

Typical Wegovy escalation: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg (about 4 weeks per step).
Timeframe expectation:

Treat timeline output as a planning range, not a hard deadline.
Plateau behavior:

A slower patch in months 4–6 is common even with good adherence.

Using this as a Zepbound weight loss calculator

Select Zepbound and use the dose you are actually on right now. Higher-dose tiers may project faster average loss, but real-world progress still tends to come in waves. This estimate is most useful for checking overall direction over months, not judging success week to week.

Dose context:

Zepbound projections align with trial-style ranges from 2.5 to 15 mg weekly.
Timeframe expectation:

Use the month estimate as a realistic window, not a promise.
Plateau behavior:

Temporary stalls can still happen during dose changes and adaptation phases.

Using this as an Ozempic weight loss calculator

Choose Ozempic if that is what you are taking, then match your current weekly dose. Because Ozempic dosing for diabetes is generally lower than Wegovy obesity dosing, projected weight loss may look more gradual. That does not mean poor response; it usually reflects dose intensity and timeline differences.

Dose context:

Ozempic entries here reflect lower semaglutide dose tiers than Wegovy.
Timeframe expectation:

Expect a steadier, slower trend compared with higher-dose obesity protocols.
Plateau behavior:

Plateaus can still occur and are often managed with consistency and provider-guided adjustments.

Using this as a Mounjaro weight loss calculator

Pick Mounjaro and set the dose you are currently using. Like Zepbound, Mounjaro uses tirzepatide, so projections can look stronger at higher tiers, but individual response still varies a lot. Think in terms of monthly trajectory, not daily scale noise.

Dose context:

Mounjaro projections follow weekly tirzepatide tiers from 2.5 to 15 mg.
Timeframe expectation:

The most useful signal is trend direction over 8–12+ weeks.
Plateau behavior:

Short stalls are common and do not cancel out longer-term progress.

What Affects Weight Loss Rate & Why Results Vary

Factors That Influence Outcomes

Trial data is population-level. Your own timeline depends on several things.

Starting Weight & BMI:

Higher starting weight may correlate with greater absolute loss; percentage loss varies by individual.
Medication & Dose:

Tirzepatide at higher doses generally produces greater mean loss than semaglutide in trials. Dose escalation and maintenance matter.
Lifestyle:

Diet quality, physical activity, sleep, and stress all influence outcomes. Medication supports, not replaces, lifestyle changes.
Genetics & Adherence:

Response varies by genetics. Missing doses or stopping early affects results.

Understanding the Plateau: Months 4–6

Why Progress Often Slows

Many GLP-1 users notice a slowdown or stall in months 3–6. This is common and does not necessarily mean the medication has stopped working. Want to compare GLP-1 projections against traditional caloric deficit models? Use our Calorie Calculator.

Metabolic Adaptation:

As you lose weight, your body burns fewer calories. The same deficit produces slower loss.
Water Weight:

Initial rapid loss often includes water. As that stabilizes, weekly loss may appear smaller.
Dose & Time:

Dose escalation takes weeks. You may not yet be at your maintenance dose. Plateaus can also precede another drop.
What to Do:

Discuss with your provider. Avoid changing dose on your own. Focus on consistency, diet, activity, and adherence, rather than day-to-day scale changes.

Clinical Trial Data: STEP & SURMOUNT

Cited Sources

We derive weekly loss rates from trial percentages: rate = (start weight × p%) ÷ trial weeks; weeks to goal = weight to lose ÷ rate. Trial data:

STEP Trials (Semaglutide/Wegovy):

STEP 1–5 evaluated semaglutide 2.4 mg for obesity. Mean weight loss ~14–17% over 68–104 weeks. Ozempic (lower doses) showed smaller mean loss.
SURMOUNT Trials (Tirzepatide/Zepbound):

SURMOUNT 1–2 evaluated tirzepatide 5, 10, 15 mg for obesity. At 15 mg: ~21% mean weight loss over 72 weeks. At 10 mg: ~19.5%; at 5 mg: ~15%.
Limitation:

Trial populations may differ from real-world users. Individual results vary. This calculator provides estimates only.

GLP-1 Weight Loss Calculator FAQ

How long does it take to lose 50 lbs on Wegovy?

At the STEP trial rate of ~14.9% mean weight loss over 68 weeks, a 250 lb person would lose ~37 lbs in 68 weeks. For 50 lbs, timeline depends on starting weight: a 350 lb person might approach 50 lbs in ~68 weeks; a 220 lb person would take longer (since 14.9% of 220 is ~33 lbs). With plateau adjustment (30% slower during months 4–6), add roughly 4–6 months. Individual results vary; use this calculator with your weight for an estimate.

What is a GLP-1 plateau and how do I break it?

A GLP-1 plateau is a period when weight loss slows or stalls, often around months 4–6. Causes include metabolic adaptation (fewer calories burned at a lower weight), reduced water loss, or not yet being at maintenance dose. To break it: stay consistent with injections and diet; discuss dose titration with your provider; increase protein and resistance training to preserve muscle; and avoid drastic calorie cuts. Plateaus are common, they don't mean the drug has stopped working. This calculator includes a plateau adjustment to model that slowdown.

Is Mounjaro more effective than Ozempic for weight loss?

Yes. In clinical trials, tirzepatide (Mounjaro/Zepbound) produced greater mean weight loss than semaglutide (Ozempic/Wegovy). SURMOUNT showed ~20.9% mean loss over 72 weeks at 15 mg vs STEP's ~14.9% for Wegovy 2.4 mg over 68 weeks. Mounjaro is also approved for diabetes; Zepbound is the obesity-specific formulation. Both are dual GLP-1/GIP agonists. Individual response varies, consult your provider to choose the right medication.

How does starting weight affect my timeline?

Higher starting weight typically means more absolute pounds lost (e.g., 14.9% of 300 lbs = 45 lbs vs 14.9% of 180 lbs = 27 lbs). This calculator uses trial-based percentage loss, so the weekly rate scales with your starting weight. Your timeline to a goal weight depends on how many pounds you need to lose and your medication/dose. Diet, exercise, and adherence also affect your personal timeline.

Can I use this calculator for Rybelsus (oral semaglutide)?

Rybelsus is oral semaglutide at lower daily doses (3–14 mg); trials showed less mean weight loss than injectable Wegovy (2.4 mg weekly). This calculator is calibrated for Ozempic, Wegovy, Mounjaro, and Zepbound, injectable formulations. Rybelsus results would likely be more conservative; use Wegovy or Ozempic as a rough proxy and expect longer timelines. Consult your provider for Rybelsus-specific expectations.

What happens to my weight if I stop GLP-1 medication?

Clinical trials and real-world data show that most people regain a significant portion of lost weight after stopping GLP-1 medications. These drugs support reduced appetite and calorie intake; when you stop, appetite often returns and weight can come back. Maintenance strategies include gradual dose tapering (under provider guidance), sustained lifestyle changes (diet and exercise), and sometimes continued low-dose therapy. This calculator does not model post-cessation weight changes, discuss long-term planning with your healthcare provider.

Sources & citations

References used for the calculation method and definitions. Links open in a new tab when available.

[1]

STEP 1 Trial: Semaglutide 2.4 mg for Weight Management (NEJM)

Pivotal New England Journal of Medicine trial demonstrating 14.9% mean weight loss with semaglutide 2.4 mg (Wegovy) over 68 weeks.

[2]

SURMOUNT-1 Trial: Tirzepatide for Obesity (NEJM)

Landmark NEJM trial showing 15–20.9% mean weight loss with tirzepatide (Mounjaro/Zepbound) over 72 weeks at varying doses.

[3]

STEP 5: Two-year effects of semaglutide (Nat Med)

Nature Medicine publication on longer-term semaglutide outcomes in adults with overweight or obesity.

[4]

FDA — Wegovy (semaglutide) prescribing information (NDA 215256)

Current FDA-approved labeling for Wegovy from Drugs@FDA (PDF).

[5]

FDA — Zepbound (tirzepatide) prescribing information (NDA 217806)

Current FDA-approved labeling for Zepbound from Drugs@FDA (PDF).

GLP-1 Weight Loss Calculator: Timeline & Projections

Weight & goals

Medication

Estimates

GLP-1 Weight Loss: What Clinical Trials Actually Show

GLP-1 Reality Check

How GLP-1 Drugs Work

Clinical Trial Averages vs You

The Plateau Window

Why We’re Careful